Drug
Nerandomilast Adult Formulation
Nerandomilast Adult Formulation: highest development phase Post-Market, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nerandomilast 18 mg - adult formulation NCT07570888 | Post-Market | Pulmonary Fibrosis |
Latest
No recent events.
Follow Nerandomilast Adult Formulation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.